Abstract
Aim: to assess the influence of endothelin receptor antagonist Bosentan on cellular Immunity parameters in pts with idiopathic pulmonary arterial hypertension (IPAH).
Methods: In the single-center comparative study we included 35 pts aged 35,2±9,6ys with IPAH confirmed by RHC (WHO Functional Class (FC) II-IV) without systemic inflammation signs. On top of stable therapy for at least 3 months Bosentan therapy was started 62,5 mg twice daily for 4 wks. At wk4 the patients were randomized 1:1 by the envelope method to have bosentan 125 or 250 mg/day. At baseline, at wk3 and wk12 visits the pts underwent the clinical and lab assessment (FC, 6-minute walking test (6-MWT), Echo, RHC,routine lab+CD-markers assessed by (fluorometry (Beckman Coulter FC 500).
Results: All cellular immunity parameters of IPAH pts remained within normal limits.
Conclusion: 12wk therapy with Bosentan changed CD-markers levels. The daily dose of 125mg resulted in the increase of B-lymphocytes levels and slight decrease of activated T lymphocytes, In patients treated with Bosentan 250 mg we found decreased numbers of activated B - and T-lymphocytes.
- © 2012 ERS
